Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 758,033 shares of the company’s stock, valued at approximately $3,676,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 1.06% of Zentalis Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $27,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at approximately $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Voleon Capital Management LP acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, State of Wyoming bought a new position in Zentalis Pharmaceuticals in the first quarter valued at approximately $67,000.

Analysts Set New Price Targets

ZNTL has been the topic of several recent analyst reports. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Mizuho initiated coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.75.

Insider Activity at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the transaction, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.80% of the company’s stock.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.80 on Friday. Zentalis Pharmaceuticals, Inc. has a one year low of $1.21 and a one year high of $6.95. The firm’s 50 day simple moving average is $4.37 and its 200 day simple moving average is $3.72. The company has a market cap of $272.35 million, a PE ratio of -1.95 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). Equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.